IBB Nears Resistance with Amgen, Vertex
The biotechnology sector, represented by the iShares Biotechnology ETF NASDAQ: IBB, has experienced a year of consolidation. With the ETF up just 0.8%, it has underperformed the broader market, making it one of the worst-performing sectors year-to-date. However, as the year’s second half begins, the IBB is trading just 3% away from its 52-week high…